Moderna, Inc. (BVMF:M1RN34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 91.75B +50.6% |
| Revenue (ttm) | 11.61B -30.0% |
| Net Income | -16.66B |
| EPS | -42.59 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,428 |
| Average Volume | 44,987 |
| Open | 11.46 |
| Previous Close | 11.70 |
| Day's Range | 11.46 - 12.18 |
| 52-Week Range | 6.02 - 15.53 |
| Beta | 1.06 |
| RSI | 40.92 |
| Earnings Date | May 1, 2026 |
About Moderna
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provid... [Read more]
Financial Performance
In 2025, Moderna's revenue was $1.94 billion, a decrease of -39.93% compared to the previous year's $3.24 billion. Losses were -$2.82 billion, -20.75% less than in 2024.
Financial numbers in USD Financial StatementsNews
Mixed options sentiment in Moderna with shares down 3.48%
Mixed options sentiment in Moderna (MRNA), with shares down $1.68 near $46.44. Options volume relatively light with 18k contracts traded and calls leading puts for a put/call ratio of 0.64,…
Moderna Transcript: RBC Capital Markets Global Healthcare Conference 2026
Cost reductions and strong sales in 2025 set the stage for 2026 growth, led by ex-U.S. partnerships and new vaccine launches. Key clinical milestones include durable melanoma data and upcoming regulatory decisions for flu and combo vaccines. Legal risks from IP disputes are considered low-probability.
Moderna Recognized by TIME as One of the World's Most Impactful Companies
CAMBRIDGE, MA / ACCESS Newswire / May 12, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked no. 1 on TIME's 2026 list of the World's Most Impactful Companies.
Moderna Transcript: Bank of America Global Healthcare Conference 2026
Revenue growth of up to 10% is expected in 2026, driven by mRESVIA and strategic partnerships, with breakeven targeted for 2028. Regulatory milestones, including a key flu vaccine PDUFA date and EU market expansion in 2027, support growth, while oncology and pandemic preparedness programs advance.
Moderna's AI Could Get a Hantavirus Vaccine Here Faster
Drug development has always been a slow business. A single medicine can take 10 to 15 years and cost billions before it reaches a patient.
Hantavirus outbreak: these 3 stocks are poised to rip higher
The World Health Organization's recent report of a Hantavirus cluster aboard a cruise ship departing Argentina has refocused global market attention on zoonotic respiratory pathogens. Three confirmed ...
Moderna Says It's Researching a Hantavirus Vaccine. The Drugmaker's Stock Is Surging.
Moderna's stock is rallying on hopes it could develop a hantavirus vaccine.
Early notable gainers among liquid option names on May 11th
Notable gainers among liquid option names this morning include Lumentum (LITE) $975.80 +72.00, Qualcomm (QCOM) $235.20 +16.11, Western Digital (WDC) $507.60 +27.60, Moderna (MRNA) $57.44 +3.09, and Co...
Here's how much Moderna's stock has rallied off renewed focus on hantavirus research
The public is growing increasingly concerned about the possibility that a hantavirus outbreak on a cruise could spark a new pandemic.
Moderna gains 9% as U.S. citizen tests positive for hantavirus
Shares of Moderna (MRNA) are up nearly 9% in premarket trading as the company evaluates potential treatments targeting hantavirus. According to reports, a U.S. citizen has tested positive for the…
Moderna stock soars as hantavirus fears spark outbreak trade
Moderna shares surged on Monday as investors rushed into vaccine and biotech stocks following reports of a hantavirus outbreak linked to a cruise ship, despite health authorities maintaining that the ...
Moderna Stock (MRNA) Extends Breakout amid Hantavirus Fears
U.S. pharma and biotech firm Moderna’s ($MRNA) shares climbed by about 9% in Monday’s pre-market session, extending their roughly 12% gain on Friday. The additional gains come as the U.S.
Hantavirus cases spark surge in pharma and biotech stocks — here's why
Several pharmaceutical stocks are rising in premarket trading in the wake of a hantavirus outbreak. Moderna, Inovio, Novavax, and Emergent Biosolutions rose in early market trading.
Moderna Stock Jumps. U.S. Passenger on Hantavirus Cruise Ship Tests Positive.
The U.S. health department said one passenger on a repatriation flight has tested mildly positive for the virus, while another is currently experiencing mild symptoms.
How Hantavirus Made Moderna a Must-Own Stock Again
The stock has rapidly outpaced the broader market, but the long-term implications of the hantavirus are unclear.
Moderna (MRNA) Stock Surges 14% on Hantavirus Vaccine. Here’s What Investors Should Know
Moderna ($MRNA) shares are surging 14% at the time of writing as investors react to the hantavirus and the biotech company’s early vaccine work. The virus has been back in…
Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010
Regulatory filings are under review in the U.S., Europe, Canada and Australia, with potential approvals expected to begin in 2026 CAMBRIDGE, MA / ACCESS Newswire / May 6, 2026 / Moderna, Inc. (NASDAQ:...
Moderna's mRNA flu vaccine outperforms standard shot in late-stage trial
Moderna's mRNA-based seasonal flu vaccine worked better than conventional flu shots in a late-stage international trial of more than 40,000 adults aged 50 and older, researchers reported on Wednesday...
Moderna Transcript: AGM 2026
The meeting covered director elections, executive compensation, and auditor ratification, with all proposals approved by shareholders. No relevant shareholder questions were submitted during the session.
Moderna Earnings Call Transcript: Q1 2026
Q1 2026 saw strong revenue growth driven by international partnerships and new product approvals, despite a net loss impacted by a major litigation settlement. The company reiterated up to 10% revenue growth for 2026, advanced its late-stage pipeline, and expects pivotal data readouts later this year.
Moderna Slides: Q1 2026
Moderna has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 1, 2026.
Moderna Quarterly report: Q1 2026
Moderna has published its Q1 2026 quarterly earnings report on May 1, 2026.
Moderna Earnings release: Q1 2026
Moderna released its Q1 2026 earnings on May 1, 2026, summarizing the period's financial results.
Moderna Stock Spikes After Earnings. Covid Vaccine Revenue Is a Growth Driver Again.
Moderna posts a narrower-than-anticipated loss and sharply higher revenue for the first quarter.
Moderna Reports Higher Revenue but Posts a Loss
Moderna reported an increase in revenue during the first quarter, citing higher Covid-19 vaccine sales in international markets.